MedTrace Logo

The Role of Peptide YY (PYY)in Inhibiting Food Intake.

NCT00259233 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 24

Last updated 2009-01-21

No results posted yet for this study

Summary

12 obese subjects will receive peripheral administration of placebo and 4 escalating doses of PYY1-36 and another 12 obese subjects will receive peripheral administration of placebo and 4 escalating doses PYY3-36 on 5 different test days within one week. The patients will be tested in a single blinded dose escalating protocol. Measurements of appetite, ad libitum energy intake, blood pressure and blood sampling will be performed during the test day.

Conditions

Interventions

DRUG

peripheral Peptide YY administration

Sponsors & Collaborators

  • Aditech Pharma AB

    collaborator INDUSTRY

  • University of Copenhagen

    lead OTHER

Principal Investigators

  • Arne Astrup, Professor · Department of Human Nutrition, RVAU

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
CROSSOVER

Eligibility

Min Age
20 Years
Max Age
50 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2005-03-31
Completion
2005-05-31

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00259233 on ClinicalTrials.gov